Author

M. Werner-Klein

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. A. Klein· 2 shared C. Werno· 2 shared H. Koerkel-Qu· 2 shared K. Weidele· 2 shared S. Guetter· 2 shared S. Treitschke· 2 shared A. Braun· 1 shared A. Grujovic· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. A. Klein

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization

S. Guetter, C. Koenig, H. Koerkel-Qu, A. Markiewicz, S. Scheitler, M. Katzer, M. Berneburg, P. Renner, B. Cucuruz, L. Guttenberger, V. Naimer, K. Weidele, S. Treitschke, C. Werno, H. Jaser, , M. Werner-Klein

This study identifies MCSP+ melanoma cells as early metastasis founder cells in lymph nodes and shows they activate immunosuppression to evade CD8 T cell attack.

bioRxiv · May 8, 2024Cancer Biology

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency

M. Werner-Klein, A. Grujovic, C. Irlbeck, M. Obradovic, M. Hoffmann, H. Koerkel-Qu, X. Lu, S. Treitschke, C. Koestler, C. Botteron, K. Weidele, C. Werno, B. Polzer, S. Kirsch, M. Guzvic, , C. A. Klein

The paper identifies IL6 trans-signaling as a mechanism supporting DCC survival and outgrowth during clinical latency, with microenvironmental dependencies and PIK3CA mutations linked to metastatic progression.

bioRxiv · May 28, 2020Cancer Biology